Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Δ9-tetrahydrocannabinol

Journal of Leukocyte Biology

Volumn 84, Issue 6, 2008, Pages 1574-1584

  Springs, Alison E B ^a   Karmaus, Peer W F ^a,b   Crawford, Robert B ^b   Kaplan, Barbara L F ^a   Kaminski, Norbert E ^a,b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

CD40 ligand; Cell mediated immunity; Humoral immunity; Immunopharmacology

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CD40 LIGAND; GAMMA INTERFERON; IMMUNOGLOBULIN M; INTERLEUKIN 2; TETRAHYDROCANNABINOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE DELETION; IMMUNOCOMPETENCE; IMMUNOMODULATION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANALGESICS, NON-NARCOTIC; ANIMALS; B-LYMPHOCYTES; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOGLOBULIN M; LEUKOCYTES; LYMPHOCYTES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SPLEEN; T-LYMPHOCYTES; TETRAHYDROCANNABINOL;

MUS; OVIS ARIES;

EID: 57149109403     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0508282     Document Type: Article

References (33)

1. Gaoni, Y., Mechoulam, R. (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86, 1646-1647.
2. Huestis, M. A., Gorelick, D. A., Heishman, S. J., Preston, K. L., Nelson, R. A., Moolchan, E. T., Frank, R. A. (2001) Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch. Gen. Psychiatry 58, 322-328.
3. Varvel, S. A., Bridgen, D. T., Tao, Q., Thomas, B. F., Martin, B. R., Lichtman, A. H. (2005) Δ9-Tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J. Pharmacol. Exp. Ther. 314, 329-337.
4. Kaplan, B. L., Rockwell, C. E., Kaminski, N. E. (2003) Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes. J. Pharmacol. Exp. Ther. 306, 1077-1085.
5. Rao, G.K., Kaminski, N.E. (2006) Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship. J. Pharmacol. Exp. Ther. 317, 820-829.
6. Rockwell, C. E., Snider, N. T., Thompson, J. T., Vanden Heuvel, J. P., Kaminski, N. E. (2006) Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor γ independently of cannabinoid receptors 1 and 2. Mol. Pharmacol. 70, 101-111.
7. Curran, N. M., Griffin, B. D., O'Toole, D., Brady, K. J., Fitzgerald, S. N., Moynagh, P. N. (2005) The synthetic cannabinoid R(+)WIN 55,212-2 inhibits the interleukin-1 signaling pathway in human astrocytes in a cannabinoid receptor-independent manner. J. Biol. Chem. 280, 35797-35806.
8. Zygmunt, P.M., Andersson, D.A., Hogestatt, E.D. (2002) (9-Tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. J. Neurosci. 22, 4720-4727.
9. Price, D. A., Owens, W. A., Gould, G. G., Frazer, A., Roberts, J. L., Daws, L. C., Giuffrida, A. (2007) CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum. J. Neurochem. 101, 389-396.
10. Galiegue, S., Mary, S., Marchand, J., Dussossoy, D., Carriere, D., Carayon, P., Bouaboula, M., Shire, D., Le Fur, G., Casellas, P. (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232, 54-61.
11. Shire, D., Calandra, B., Bouaboula, M., Barth, F., Rinaldi-Carmona, M., Casellas, P., Ferrara, P. (1999) Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. Life Sci. 65, 627-635.
12. Landsman, R. S., Burkey, T. H., Consroe, P., Roeske, W. R., Yamamura, H. I. (1997) SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur. J. Pharmacol. 334, R1-R2.
13. Rhee, M. H., Kim, S. K. (2002) SR144528 as inverse agonist of CB2 cannabinoid receptor. J. Vet. Sci. 3, 179-184.
14. Portier, M., Rinaldi-Carmona, M., Pecceu, F., Combes, T., Poinot-Chazel, C., Calandra, B., Barth, F., le Fur, G., Casellas, P. (1999) SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. J. Pharmacol. Exp. Ther. 288, 582-589.
15. Krylatov, A. V., Maslov, L. N., Lasukova, O. V., Pertwee, R. G. (2005) Cannabinoid receptor antagonists SR141716 and SR144528 exhibit properties of partial agonists in experiments on isolated perfused rat heart. Bull. Exp. Biol. Med. 139, 558-561.
16. Batkai, S., Pacher, P., Jarai, Z., Wagner, J. A., Kunos, G. (2004) Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors. Am. J. Physiol. Heart Circ. Physiol. 287, H595-H600.
17. Karsak, M., Gaffal, E., Date, R., Wang-Eckhardt, L., Rehnelt, J., Petrosino, S., Starowicz, K., Steuder, R., Schlicker, E., Cravatt, B., Mechoulam, R., Buettner, R., Werner, S., Di Marzo, V., Tuting, T., Zimmer, A. (2007) Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 316, 1494-1497.
18. Buchweitz, J. P., Karmaus, P. W., Williams, K. J., Harkema, J. R., Kaminski, N. E. (2008) Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/ 8/34 in the absence and presence of Δ9-tetrahydrocannabinol. J. Leukoc. Biol. 83, 785-796.
19. Jarai, Z., Wagner, J. A., Varga, K., Lake, K. D., Compton, D. R., Martin, B. R., Zimmer, A. M., Bonner, T. I., Buckley, N. E., Mezey, E., Razdan, R. K., Zimmer, A., Kunos, G. (1999) Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. USA 96, 14136-14141.
20. Lee, M., Yang, K. H., Kaminski, N. E. (1995) Effect of putative endogenous cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes. J. Pharmacol. Exp. Ther. 275, 529-536.
21. Kaminski, N. E., Holsapple, M. P. (1987) Inhibition of macrophage accessory cell function in casein-treated B6C3F1 mice. J. Immunol. 139, 1804-1810.
22. Schatz, A. R., Koh, W. S., Kaminski, N. E. (1993) Δ9- Tetrahydrocanabinol selectively inhibits T-cell dependent humoral immune responses through direct inhibition of accessory T-cell function. Immunopharmacology 26, 129-137.
23. Dunnett, C. W. (1955) A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 50, 1096-1121.
24. Bystry, R. S., Aluvihare, V., Welch, K. A., Kallikourdis, M., Betz, A. G. (2001) B cells and professional APCs recruit regulatory T cells via CCL4. Nat. Immunol. 2, 1126-1132.
25. Eddahri, F., Oldenhove, G., Denanglaire, S., Urbain, J., Leo, O., Andris, F. (2006) CD4+ CD25+ regulatory T cells control the magnitude of T-dependent humoral immune responses to exogenous antigens. Eur. J. Immunol. 36, 855-863.
26. Mesel-Lemoine, M., Cherai, M., Le Gouvello, S., Guillot, M., Leclercq, V., Klatzmann, D., Thomas-Vaslin, V., Lemoine, F. M. (2006) Initial depletion of regulatory T cells: the missing solution to preserve the immune functions of T lymphocytes designed for cell therapy. Blood 107, 381-388.
27. Buchweitz, J. P., Harkema, J. R., Kaminski, N. E. (2007) Time-dependent airway epithelial and inflammatory cell responses induced by influenza virus A/PR/8/34 in C57BL/6 mice. Toxicol. Pathol. 35, 424-435.
28. Ziring, D., Wei, B., Velazquez, P., Schrage, M., Buckley, N. E., Braun, J. (2006) Formation of B and T cell subsets require the cannabinoid receptor CB2. Immunogenetics 58, 714-725.
29. Jan, T. R., Rao, G. K., Kaminski, N. E. (2002) Cannabinol enhancement of interleukin-2 (IL-2) expression by T cells is associated with an increase in IL-2 distal nuclear factor of activated T cell activity. Mol. Pharmacol. 61, 446-454.
30. Matveyeva, M., Hartmann, C. B., Harrison, M. T., Cabral, G. A., McCoy, K. L. (2000) Δ(9)-Tetrahydrocannabinol selectively increases aspartyl cathepsin D proteolytic activity and impairs lysozyme processing by macrophages. Int. J. Immunopharmacol. 22, 373-381.
31. McCoy, K. L., Matveyeva, M., Carlisle, S. J., Cabral, G. A. (1999) Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. J. Pharmacol. Exp. Ther. 289, 1620-1625.
32. Condie, R., Herring, A., Koh, W. S., Lee, M., Kaminski, N. E. (1996) Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and IL-2 expression in the murine T-cell line, EL4.IL-2. J. Biol. Chem. 271, 13175-13183.
33. Jan, T. R., Farraj, A. K., Harkema, J. R., Kaminski, N. E. (2003) Attenuation of the ovalbumin-induced allergic airway response by cannabinoid treatment in A/J mice. Toxicol. Appl. Pharmacol. 188, 24-35.